MSH2 and adenoma: Our adenoma incidence findings of MSH2/EPCAM carriers are in line with others previously documented in the literature; however, as stated, we did not observe a statistically significant difference in prevalence of adenoma between MMR variants on multivariate analysis when the entire follow-up for the cohort was considered.